מאמר חדש מצביע על קשר ישיר בין מתן הטיפול המונע נגד הRSV להפחתה במקרי הציפצופים החוזרים (אסתמה).

Palivizumab Prophylaxis, Respiratory Syncytial Virus, and Subsequent Recurrent Wheezing

Eric A.F. Simoes, MB, BS, DCH, MD⁎a, Jessie R. Groothuis, MD†ab, Xavier Carbonell-Estrany, MD, PhD‡a, Christian H.L. Rieger, MD§a, Ian Mitchell, MA, MB, ChB∥a, Linda M. Fredrick, MS¶c, Jan L.L. Kimpen, MD, PhD⁎⁎a 

Objective

Children who experience respiratory syncytial virus (RSV) lower respiratory tract infections (LRTIs) early in life have high rates of subsequent recurrent wheezing. Palivizumab, an anti-RSV monoclonal antibody, has 78% to 80% efficacy in preventing RSV hospitalization in premature infants without chronic lung disease. We hypothesized that palivizumab, by ameliorating or preventing early RSV LRTI in preterm infants, might decrease later recurrent wheezing.

לאבסטרקט באתר journal of pediatrics